CHINA PHARMA RECEIVES SFDA APPROVAL FOR NAUSEA DRUG

China Pharma Holdings announced it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market its granisetron hydrochloride injection product.

Granisetron hydrochloride is indicated for the prevention of nausea and vomiting associated with radiation treatment and chemotherapy in cancer patients. It is a highly selective receptor antagonist against 5-hydroxytryptamine 3 (5-HT3), which is produced during chemotherapy and radiation treatment and triggers emetic reactions.

China Pharma intends to market this product exclusively within the greater China area. Currently, the sales statistics for granisetron products in China are not available; however, the market for injectable granisetron hydrochloride is valued at more than $1 billion in the U.S. and Canada, according to the company.

China Pharma develops, manufactures, and markets generic and brand biopharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, vascular diseases, CNS and other prevailing diseases.